Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acyclovir + flucloxacillin is a combination of two pharmaceutical agents with distinct mechanisms of action. Acyclovir is an antiviral small molecule that acts as a guanosine analog, inhibiting viral DNA polymerase and thereby blocking replication of herpesviruses such as herpes simplex virus (HSV) and varicella zoster virus (VZV)[2]. Flucloxacillin is a narrow-spectrum beta-lactam antibiotic in the penicillin class, primarily active against Gram-positive bacteria including Staphylococcus aureus (excluding MRSA), by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins[7]. This combination may be considered in clinical scenarios where both viral (herpetic) and bacterial infections are suspected or confirmed. There are no known direct pharmacological interactions between these two drugs; they can be co-administered safely when clinically indicated[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acyclovir + flucloxacillin.